Macquarie Upgrades ResMed to Outperform

Macquarie analyst David Bailey upgrades ResMed (NYSE:RMD) from Neutral to Outperform.

Macquarie analyst David Bailey upgrades ResMed (NYSE:RMD) from Neutral to Outperform.

Total
0
Shares
Related Posts